{"name":"Imclone Systems","permalink":"imclone-systems","crunchbase_url":"http://www.crunchbase.com/company/imclone-systems","homepage_url":"http://www.imclone.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":1984,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"clinicaltrials@imclone.com","phone_number":"212.645.1405","description":"","created_at":"Sun Sep 13 01:57:02 UTC 2009","updated_at":"Fri Jul 15 20:19:27 UTC 2011","overview":"<p>A leader in therapeutic antibodies, ImClone Systems (also called &#8220;the company&#8221;) is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.</p>\n\n<p>Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUXÂ®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development.</p>\n\n<p>Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly&#8217;s global capabilities. ImClone&#8217;s pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years.</p>\n\n<p>ImClone&#8217;s research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company&#8217;s state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone&#8217;s Branchburg campus also houses it clinical development and administration operations. The company&#8217;s research headquarters are based in New York City and it has international operations in Europe. </p>","image":{"available_sizes":[[[146,150],"assets/images/resized/0014/4460/144460v1-max-150x150.jpg"],[[150,154],"assets/images/resized/0014/4460/144460v1-max-250x250.jpg"],[[150,154],"assets/images/resized/0014/4460/144460v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$0","funding_rounds":[],"investments":[],"acquisition":{"price_amount":7133620000,"price_currency_code":"USD","term_code":null,"source_url":"http://www.internationallawoffice.com/deals/Detail.aspx?g=d5088ab1-4d01-4dc2-aa34-2fb22e5923f0","source_description":"Cap Funding Report","acquired_year":2008,"acquired_month":11,"acquired_day":24,"acquiring_company":{"name":"Eli Lilly","permalink":"eli-lilly","image":{"available_sizes":[[[102,60],"assets/images/resized/0005/9606/59606v1-max-150x150.png"],[[102,60],"assets/images/resized/0005/9606/59606v1-max-250x250.png"],[[102,60],"assets/images/resized/0005/9606/59606v1-max-450x450.png"]],"attribution":null}}},"acquisitions":[],"offices":[{"description":"","address1":"180 Varick Street","address2":"6th Floor","zip_code":"10014","city":"New York","state_code":"NY","country_code":"USA","latitude":40.727438,"longitude":-74.005301}],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}